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Abstract 
The current culture in health care is focused on patient safety and on delivering quality health 
care across the continuum of care. However, a culture of safety by itself cannot create change 
within an organization. Venous thromboembolism (VTE) requires coordination of care across 
multiple providers supported by a system that assists in the process of delivering and tracking 
outcomes of care. In this paper, we describe the implementation and use of safe practice 
interventions for patients who have been diagnosed with VTE or are at risk for VTE. In 
particular, we describe the use of the evidence-based, system-supported, interactive VTE Safety 
Toolkit—which includes diagnostic, preventive, and therapeutic algorithms—and the On-line 
Provider Training Module on VTE Prophylaxis, which is a mandatory Web-based VTE 
educational intervention for all providers. We describe how organizations and providers can use 
the VTE Safety Toolkit and On-line Provider Training Module on VTE Prophylaxis to identify 
business process that can be changed and create a mechanism to track provider and system 
performance and thereby improve patient safety and accountability around VTE.  
 
Introduction 
Venous thromboembolism (VTE) encompasses deep vein thrombosis (DVT) and pulmonary 
embolism (PE). VTE is one of the most common clinical disorders among both inpatients and 
outpatients, and PE is the most common preventable cause of death among hospitalized patients 
in the United States.
1 Approximately 2.5 million cases of DVT and 600,000 cases of PE are 
diagnosed per year in the United States. About 30 percent to 40 percent of postoperative patients 
will develop some form of DVT, and VTE is associated with more than 300,000 hospitalizations 
annually.
2, 3, 4 Approximately two-thirds of patients with symptomatic VTE manifest DVT 
alone, whereas one-third of patients manifest PE.  
Appropriate prophylactic regimens for many different patient groups have been determined by 
randomized clinical trials, as has the appropriate treatment of established DVT.
5, 6 Errors from 
omission of prophylaxis or objective diagnostic testing, or inadequate treatment are estimated to 
result in significant harm to hospitalized patients. A fundamental understanding of prophylaxis, 
diagnosis, and treatment is necessary for providers throughout the continuum of patient care. 
Given the magnitude of the problem, it is not surprising that the diagnosis and management have 
been better defined for VTE than for other common diseases.  
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Patient safety has been a major focus of the Agency for Healthcare Research and Quality 
(AHRQ). Several clinical guidelines for patient safety have been developed and implemented in 
health care organizations.
7, 8, 9, 10, 11 Diverse approaches to organizational change have also been
introduced.
 
7, 8, 9, 10, 11 However, patient safety remains a challenge because of the difficulty in 
sustaining organizational change to support new initiatives. Patient safety issues associated with 
the prevention and management of VTE continue to pose a challenge in most U.S. hospitals.  
The purpose of this project was to increase the implementation of safe practice interventions for 
patients at risk for or diagnosed with VTE using the evidenced-based and system-supported 
interactive VTE Safety Toolkit and On-line Provider Training Module on VTE Prophylaxis. 
Multidisciplinary clinical and research teams in partnerships among the University of 
Washington Medical Center (UWMC), UW School of Nursing, and the Center for Health 
Sciences Interprofessional Education and Research have developed and implemented the VTE 
Safety Toolkit locally through a public Web site (http://vte.washington.edu/) for providers and 
patients.  
This project was intended to inform providers, patients, payers, policymakers, and the public 
about how these safe practice interventions can be implemented successfully in diverse health 
care settings, leading to safer and better health care for all Americans. In this paper, we discuss 
the development of evidence-based tools and educational interventions around the clinical 
diagnosis of VTE. The processes for implementation and the plans for local, regional, and 
national dissemination are also discussed. The dissemination of results for the pre-
implementation data collection period of the VTE Safety Toolkit and On-line Provider Training 
Module on VTE Prophylaxis will be reported in peer review journals. 
 
VTE Safety Toolkit: What Is It? 
The VTE Safety Toolkit consists of diagnostic, preventive, and therapeutic algorithms; a 
mandatory Web-based VTE educational intervention for all providers; patient educational 
materials; and provider communication strategies to promote continuity of care. The toolkit is 
divided into provider, patient, and system sections. The provider component includes educational 
tools for increasing knowledge on the assessment of risk for developing VTE, using VTE 
prophylaxis strategies, understanding diagnostic strategies for VTE, treating acute VTE in 
inpatients and outpatients, and managing patients after treatment. The patient component consists 
of educational tools for improving knowledge about the prevention of VTE and about outpatient 
treatment options. Systems components include clinical tools, infrastructure support, and expert 
consultants for improving communication between providers and patients and for improving the 
coordination of care throughout the continuum. Although they are not “tools” per se, the 
infrastructure support consists of an integrated clinical database, standardized reporting 
strategies, quality improvement tools, and computerized logbooks. Each element of the VTE 
Safety Toolkit was designed to address a specific safety issue related to VTE diagnosis, 
prevention, and management.  
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The VTE Safety Toolkit contains 10 components that are evidence-based guidelines for 
preventing, diagnosing, treating, and educating patients and providers about VTE. The 
components are as follows:  
•  VTE prophylaxis guidelines. 
•  VTE risk assessment tool. 
•  DVT diagnostic algorithm. 
•  PE diagnostic algorithm. 
•  HIT (heparin-induced thrombocytopenia) assessment. 
•  VTE treatment pathway. 
•  DVT outpatient treatment order set. 
•  Vascular laboratory requisition. 
•  Neural-axial anesthesia guidelines. 
•  Patient education (prevention and treatment) pamphlets.  
Due to space constraints, a brief description of 4 of the 10 tools—including the VTE prophylaxis 
guidelines, VTE risk assessment tool, DVT and PE diagnostic algorithms, and the VTE treatment 
pathway—are presented here. The remaining guidelines and information about the toolkit can be 
found at http://vte.washington.edu/. 
The VTE Prophylaxis Guidelines are used to assess every patient upon admission and discharge 
for their risk of developing VTE and for recommending the type, dose, timing, and duration of 
anticoagulants. If a patient presents with contraindications to pharmacologic prophylaxis (e.g., 
heparin, warfarin), mechanical prophylaxis—such as sequential compression devices or 
graduated compression stockings—is recommended. If a patient presents with signs and 
symptoms of DVT, the DVT diagnostic algorithm can be utilized. Before objective diagnostic 
studies are ordered, providers must complete a history and physical examination and a DVT risk 
assessment, and they must rate the clinical probability of DVT using the Wells scoring system.
12  
The PE diagnostic algorithm is very similar to the acute DVT algorithm. The provider first 
obtains the patient’s history and physical examination, a chest x-ray, and arterial blood gases; 
completes the PE risk factor assessment; and rates the clinical probability of PE using the Wells 
PE scoring algorithm.
13 If a patient suspected of PE presents with leg symptoms, then a venous 
duplex ultrasound is ordered. If no leg symptoms are present, a spiral computed tomography 
(CT) scan is recommended as the first diagnostic test. For patients who cannot receive contrast 
dye, a ventilation and perfusion scan can replace the spiral CT scan.  
The VTE treatment pathway is utilized when a patient has been diagnosed with acute DVT or 
PE. After the initial diagnosis is made, baseline blood tests—including prothrombin time (PT) 
with international normalized ratio (INR), partial thromboplastin time (PTT), and complete 
blood count (CBC)—are obtained to ensure correct dosage of anticoagulation. If a patient is 
eligible for outpatient treatment, low molecular-weight heparin is recommended; inpatients are 
typically treated with unfractionated heparin, intravenously or via subcutaneous injections, and 
transitioned to warfarin following discharge. Warfarin is subsequently used for several months 
after the initial diagnosis of DVT or PE to prevent recurrent VTE.
14 In addition to pharmacologic 
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treatment, compression stockings with a pressure of 30 to 40 mm Hg at the ankle are used for 2 
years to prevent post-thrombotic syndrome.  
 
Methods 
VTE Diagnostic and Treatment Standards  
Even though strong direct evidence is available to guide the management and prevention of 
VTE, morbidity and mortality remain high.
15, 16,17 A considerable body of literature informs 
practice about VTE risk assessment, prophylaxis, diagnosis, and treatment.
14, 18, 19, 20, 21,  22, 23, 24
Evidence-based guidelines, graded by strength of evidence and methodologic quality of 
evidence, have been established by the American College of Chest Physicians (ACCP) 
Conference on Antithrombotic and Thrombolytic Therapy.
 
14, 19 These guidelines, in their seventh 
edition in 2004, served as the basis for the development of the VTE Safety Toolkit and the On-
line Provider Training Module on VTE Prophylaxis.
14, 19, 25  
The ACCP guidelines summarize the full body of evidence regarding the risk of VTE associated 
with various medical illnesses and surgical procedures and have established a clear set of risk 
factors that can be used for stratifying VTE risk in individual patients.
19 Strategies for 
prophylaxis in various clinical settings are defined, including mechanical and pharmacologic 
methods, with appropriate dose and duration of therapy. Treatment standards have also been 
clearly defined for both inpatients and outpatients, based on a complete review of all available 
evidence.
14, 19, 25 
Development of the VTE Safety Toolkit 
Despite substantial literature concerning appropriate management, VTE has been identified as an 
area of concern by several national groups involved with patient safety or quality improvement 
(i.e., Surgical Care Improvement Projects, National Quality Forum, The Leapfrog Group for 
Patient Safety, and The Joint Commission). When the UWMC found an increased incidence of 
postoperative VTE, addressing this clinical problem became a major priority. Data from previous 
VTE studies at UWMC, including a 15-year natural history of DVT study, demonstrated 
multiple problems with the diagnosis, management, and prevention of VTE at the level of the 
provider, patient, and system.  
VTE is not a new clinical problem, but it is a unique clinical problem that requires coordination 
of care across multiple locations (in hospitals, in outpatient clinics, at home) by multiple 
providers (nursing, medicine, pharmacy, and surgery) and is supported by a system that assists in 
the process of delivering care. A group of interprofessional providers and researchers were 
responsible for the development of the pathways, order sets, guidelines, and patient handouts that 
make up the VTE Safety Toolkit. Local experts in thrombosis, vascular diagnostics, and 
anticoagulation were called upon in this process. The VTE Safety Toolkit was developed based 
on clinical evidence and established guidelines. 
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Results   
Issues and Challenges of the VTE Safety Toolkit 
The VTE Safety Toolkit has faced and will continue to face various issues and challenges during 
the development and implementation stages. In prior studies of VTE management led by our lead 
author, Dr. Zierler, the most common challenges were related to changing individual provider 
behavior, rather than changing business practices within organizations. Integrated pathways for 
DVT management, which were developed prior to the development of the VTE Safety Toolkit, 
were disseminated to multiple groups of providers without a plan to provide infrastructure 
support for use of the pathways. Although providers were given physician order sets, there was 
no efficient way to determine utilization of the order set, except to physically review paper 
records. The original pathways did not include risk assessment or prophylaxis pathways for 
preventing acute VTE because they focused on the outpatient treatment of acute DVT.  
The risk for VTE rises during illness and during treatment for illness. Prevention, diagnosis, and 
treatment of VTE should occur not only during acute hospital care, but also before and after 
hospitalization. Patients are often referred to the UWMC and Harborview Medical Center 
(HMC) for only a portion of their care, and they return to their communities for further 
treatment. Thus, plans to reduce VTE risk should also involve external community providers. 
This issue has been addressed. Plans for implementation of the VTE Safety Toolkit include 
providing access to external community providers and patients. Patients need to be recruited to 
participate in their care, and they can be taught to identify risks, signs, and symptoms of VTE; 
adhere to the appropriate dose of anticoagulation; and seek medical care in a timely fashion.  
In order to achieve the goal of increasing the implementation of safe practice interventions for 
VTE in the clinical setting, the VTE Safety Toolkit was developed with these significant changes 
from the preliminary studies. However, the VTE Safety Toolkit has proceeded with some 
expected challenges that simply cannot be addressed without institutional changes. The lack of 
an integrated clinical information system to view a patient’s complete medical record needs to be 
addressed. The documentation of care and clinical outcomes are located in several different 
computer-based programs, one for providers, one for nurses, one for pharmacists, etc. The lack 
of integration of the existing information systems requires multiple steps to abstract 
comprehensive patient data and makes it difficult to track changes related to care in an efficient 
manner. A new integrated clinical information system is being programmed and piloted within 
small groups of providers at UWMC and HMC, but neither system has a fully integrated 
information component.  
A goal to improve the standards of care for hospitalized patients at risk for VTE has been to 
create one admissions assessment form. Currently, each discipline creates an intake assessment 
form specific to their unit. The VTE clinical and research team has suggested the development of 
one form that could be standardized for use across the organization. Currently, not every unit 
requires that a patient be assessed for VTE risk. This is because the form that they use does not 
include the question of VTE risk, and changing the form incurs a substantial cost. As the 
organization moves toward adopting an integrated information system, it should be possible to 
include a standard form that requires a response to whether a patient has been assessed for VTE 
risk. This will be necessary because assessing each patient for VTE risk and prescribing 
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appropriate pharmacologic prophylaxis for VTE are now incorporated into the Center for 
Medicare & Medicaid’s (CMS) pay-for-performance initiative (as of July 1, 2007), giving 
providers and health care organizations a financial incentive to document these procedures.  
Online Provider Training Module on VTE Prophylaxis 
As part of the patient safety movement, the UWMC and HMC administration decided that all 
resident and attending physicians needed training relative to VTE, since VTE was the single 
most preventable condition in U.S. hospitals. Moreover, less than 30 percent of eligible UWMC 
patients were actually receiving VTE prophylaxis.  
This training has been designed as a randomized trial comparing the addition of interactive VTE 
case studies with an online standard didactic training module on VTE prophylaxis. All UW 
providers—residents and attending physicians—will participate in this quality improvement 
intervention and education evaluation study. Providers will receive an e-mail from the office of 
the Center for Clinical Excellence with instructions and the rationale for completing the online 
VTE prophylaxis training. Providers will log in to a protected Web site using their personal 
hospital username and password. A brief statement on the log in site (front page) explains that 
the VTE prophylaxis training module involves a research component (survey) and that we will 
be testing two different methods of online educational training that will affect future training 
module designs. All participants in this study will be aware of how collected data will be used; 
they will be able to opt out of having their data included in the research database; but they will 
not be permitted to opt out of the training.  
Randomization will occur at the time of log in, and the provider will be assigned to either the 
control (passive didactic training only) group or the intervention (passive didactic training and 
interactive case studies) group. After logging in, all providers will be asked to complete a brief 
demographic questionnaire and pretest to measure their knowledge about VTE prophylaxis and 
prevention.  
The pretest comprises 10 questions relating to the content of the passive and interactive “training 
slides” on VTE prophylaxis. All providers in the control and intervention groups will be shown 
nine (tutorial) passive, didactic slides with information on VTE prevention [similar to Health 
Insurance Portability Accountability Act (HIPAA) training—information with no immediate 
feedback]. Providers who are randomized to the intervention group will then review interactive 
case studies followed by the postassessment test. The total number of interactive cases depends 
on the number they answer correctly. There are four content areas and four cases for each 
content area, for a total of 16 interactive slides. The providers need to pass one from each content 
area correctly; the pass rate is a score of 80 percent or higher. Providers in the control group will 
complete the postassessment test following the tutorial slides.  
The Director of the Center for Clinical Excellence will ask for resident (champion) physician 
volunteers to begin piloting the On-line Provider Training Module on VTE Prophylaxis, and it 
became mandatory in spring 2008, with post-implementation data collection planned to begin in 
September 2008. The goal of this research is to increase the percentage of hospitalized patients 
without contraindications who receive anticoagulation prophylaxis by increasing provider 
knowledge about VTE prophylaxis. After the evaluation, the training module will be added to the 
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VTE Safety Toolkit and will be available to other academic medical centers for provider training 
on VTE prophylaxis. 
The implementation of the On-line Provider Training Module on VTE Prophylaxis demonstrates 
a change in business practices at UWMC and HMC. The VTE training module is the first 
mandatory education module (similar to HIPAA training) to be implemented for providers using 
a new Web-based learning management tool. Both medical centers are planning three mandatory 
educational provider training modules to address concerns about standardized training and 
patient safety; the VTE prophylaxis module is the first of these. Researchers with training in 
educational psychology and evaluation assisted with the development of the training module, 
including the pre- and post-assessment questions.  
 
Implementation and Dissemination of Interventions 
Implementation Plan  
Provider education is a key component of the “preadoption stage” as outlined by Greenhalgh, et 
al.
26 In order for individuals involved in a system-level adoption to fully participate, they must 
be aware of the innovation, have adequate information to see how it affects their practice and 
how they would use it, and have access to support systems to help them use it. The clinical 
experts who finalized the VTE Safety Toolkit elements provided the didactic content and 
references for educational modules about each aspect of risk, diagnosis, management, and 
prophylaxis (see “About Us” on VTE Safety Toolkit Web site: http://vte.washington.edu/).  
The educational component of the toolkit will be introduced through special grand rounds 
presentations by opinion leaders/champions for each of the clinical services that will become 
end-users. Because all of the medical services grand rounds include providers from the 
community and other UW teaching hospitals, these will also serve as initial dissemination 
vehicles to providers outside of UW Medicine. Nursing, pharmacy, and other relevant provider 
professions also have grand rounds or monthly meetings that will be accessed for the “kick-off” 
presentations.  
UWMC and HMC providers receive continuing education credit for the grand rounds attendance, 
and we are currently investigating whether providers can receive additional continuing education 
credits for completing the On-line Provider Training Module on VTE Prophylaxis. These 
modules will be organized around illustrative cases so they actively apply evidence-based 
practices and engage in higher level learning activities, rather than simply reviewing the content. 
These modules also will be tied to appropriate UWMC intranet sites to assist providers when 
they are faced with retrieving appropriate evidenced-based practice guidelines in the course of 
patient care. In addition, a quarterly newsletter produced by the UWMC Pharmacy will provide 
up-to-date information on the implementation process.  
Individual providers will be asked to provide feedback to the UW Center for Clinical 
Excellence’s reporting mechanism throughout the process to assess the effectiveness of 
dissemination and implementation. UWMC will continue to benchmark the incidence of VTE 
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quarterly, and research assistants will continue to monitor data on the incidence of VTE and the 
adequacy of prophylaxis and management of VTE. 
External providers will have access to the VTE Safety Toolkit through the use of a Web-based 
program sponsored by the UWMC called ULINK, a referral program called MEDCON, and 
from the discharge summary that will have a URL linking the referring physician to a UWMC 
Web page that will house the VTE Safety Toolkit. The ULINK program gives referring providers 
instant access to patient information and updated records from the UWMC, HMC, and the 
Seattle Cancer Care Alliance, as long as their patients give permission. MEDCON is a toll free 
consultation and referral service of the UW School of Medicine and its primary teaching 
hospital. As a major resource for medical education, research, and patient care, the UW School 
of Medicine places particular importance on its communication with the practicing physicians in 
the Pacific Northwest and the WWAMI (Washington, Wyoming, Alaska, Montana, and Idaho) 
region. We will link the VTE Safety Toolkit to the UWMC patient care Web page under “Refer a 
Patient” so that external providers can have access to the educational tools. 
Dissemination Plan  
Internal dissemination target audiences are inpatient and clinic providers. The dissemination plan 
has been developed using the planning tool developed by the AHRQ Patient Safety Research 
Coordinating Committee.
27 The AHRQ Dissemination Planning Tool is an integral part of 
dissemination for the VTE Safety Toolkit within UWMC; it will be utilized for regional and 
national dissemination in the years following the end of the funded project. The AHRQ 
Dissemination Planning Tool is grounded in research regarding effective dissemination of 
innovations discussed in the background of this proposal. The AHRQ Dissemination Planning 
Tool helps researchers consider six elements of effective dissemination: packaging of results, 
identifying endusers, engaging connector organizations, identifying and overcoming barriers to 
implementation, developing success measures, and allocating resources to implement the plan.  
The plan also has two phases. Phase I involves dissemination of the VTE Safety Toolkit and On-
line Provider Training Module on VTE Prophylaxis, which is an integral part of implementation 
to internal users. Phase II involves dissemination to more distant external users. These phases are 
iterative in that the initial implementation strategies and tools will be revised based on initial 
Phase I findings. The dissemination plan was developed within the framework proposed by 
Greenhalgh, et al.,
26 and is positioned between the “help it happen” and the “make it happen” 
ends of the continuum.  
The six key components of the Dissemination Planning Tool can be briefly described as follows: 
1.  Research findings and products: What is going to be disseminated? The products to be 
disseminated are the VTE Safety Toolkit and On-line Provider Training Module on VTE 
Prophylaxis. As described earlier, these Phase I products are based on research findings.
14, 19 
The Phase II products will be accomplished following the analysis of the post-
implementation period and will be disseminated at national meetings, on the AHRQ Patient 
Safety Research Coordinating Center site, and through publications. Phase II products will 
consist of implementation strategies (based on lessons learned) and the two interventions 
VTE Safety Toolkit and On-line Provider Training Module on VTE Prophylaxis. 
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2.  End-users: Who will apply the findings and products in practice? For the implementation in 
Phase I, the clinical providers and their patients in the UWMC and HMC inpatient and 
ambulatory care sectors are the endusers. The providers come from the full range of clinical 
services and specialties where patients are at risk for or develop VTE as described earlier in 
the application. Providers are health care professionals involved in directly or indirectly 
providing care to these patients at any phase: prevention through management. They include 
physicians, nurses, and pharmacists. Patients include any recipients of assessment, treatment, 
or preventive measures for VTE from either UWMC or HMC providers.  
End-users for Phase II expand to AHRQ, to providers nationally, and to actual and potential 
patients nationally. AHRQ is committed to national dissemination, and we will provide the 
materials in forms that can be disseminated widely, in a variety of technical formats, and 
using a variety of technologic means.  
3.  Dissemination partners: Dissemination partners include individuals and organizations 
through which endusers can be reached. Phase I partners are the UWMC, HMC, Center for 
Clinical Excellence, UW Center for Health Science Education & Research, and the providers 
and patients involved in the implementation. During Phase II, AHRQ will be added as a 
dissemination partner. Other national organizations through which we might reach endusers 
include the National Patient Safety Organization, AHRQ-funded dissemination centers, 
National Quality Forum, and the network of patient safety researchers.  
4.  Communication strategies: What is the best ways to convey the research findings and 
products to end users? For Phase I, these involve a variety of in-person and online means to 
reach individual patients and providers, who ultimately are the adopters of this innovation in 
terms of choosing to use the recommendations or not. Research has shown that a variety of 
strategies are needed to link this systematic change with individual users and their perceived 
needs for information and tools. As noted in the Methods section, we will have formal 
didactic sessions in the form of grand rounds within and among the professional provider 
groups; written newsletters and e-mail notices; provider supports, reminders and forms 
within the electronic medical record; champions and dedicated support to the users; Web 
sites with factual and case-based material. Printed summaries of recommendations or 
prescriptions will also be available, along with Web-based materials, informative posters and 
buttons, and other visual displays. Phase II will add a package of implementation strategies 
based on our lessons learned and the evaluation of Phase I implementation strategies. 
5.  Dissemination Plan. As described earlier, we used the evidence-based planning tool 
developed by the AHRQ Patient Safety Research Coordinating Committee
27 to develop our 
dissemination plan. According to our plan, Phase 1 will reach internal users, and Phase II will 
target external, distant users. The AHRQ Dissemination Planning Tool will be used to guide 
regional and national dissemination in future years. 
6.  Evaluation: The evaluation will determine what did and did not work with respect to 
dissemination. The outcomes described in the specific aims are the primary method of 
evaluating actual usage and the effect of the Phase I dissemination. These outcomes include: 
(1) an increased percentage of hospitalized patients whose VTE risk factors are assessed and 
documented upon admission and on discharge; (2) an increased percentage of hospitalized 
patients without contraindications who receive prophylaxis for VTE; (3) a decreased volume 
of inappropriately ordered venous duplex scans, along with an increased rate of duplex scans 
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ordered for patients for whom it is appropriate; (4) an increased percentage of patients with a 
diagnosed VTE who receive appropriate therapy in the hospital and are discharged with 
appropriate outpatient therapy; and (5) improved provider knowledge about VTE prophylaxis 
and improved satisfaction with mandatory educational interventions through the use of 
interactive case studies. All of these evaluations can be extracted from the computerized 
record, quality improvement data (results of provider educational intervention), and provider 
surveys. 
 
Discussion 
Translation of Science Into Practice (Diffusion and Dissemination)  
Although the evidence that should inform multidisciplinary practice in prophylaxis, diagnosis, 
and treatment of VTE is abundant, the adoption of relevant evidence-based guidelines into 
practice is limited. Why then do we think that implementation of the VTE Safety Toolkit and On-
line Provider Training Module on VTE Prophylaxis will result in a higher rate of adoption than 
that achieved with prior efforts?  
The strong commitment of the UWMC and HMC to improving patient safety provides a context 
in which multiple determinants of successful adoption exist.
26 Namely, these organizations see 
the goals of this project as compatible with their organizational goals of reducing VTE and of 
improving safe practice interventions with this patient population.  
Observable and achievable outcomes directly related to the clinical work of the multiple 
disciplines involved in the care of this patient population will be measured. The VTE Safety 
Toolkit will be integrated into the normal working tools of the providers and will be 
“augmented” with customization, training, and the clinical equivalent of a “help desk.” The 
implementation of the On-line Provider Training Module on VTE Prophylaxis is an innovative 
method to change the business practices for providers at UWMC and HMC. The fact that senior 
administrators at both medical centers have agreed to implement the On-line Provider Training 
Module on VTE Prophylaxis as the first mandatory educational intervention (similar to HIPAA 
training) for an identified patient safety problem signals to providers that VTE prevention is a 
problem that has been recognized as an organizational one and, therefore, requires an 
organizational solution. Withholding patient care privileges for providers pending the successful 
completion of the On-line Provider Training Module on VTE Prophylaxis is evidence that the 
organization is looking for measurable changes and accountability.  
The patient safety movement has, in large part, promised changes in the delivery of care based 
on an organization adopting a “culture of safety.” In 2007, at the National Patient Safety 
Foundation’s annual meeting in Washington, DC, a panel of experts commented on the fact that 
change will occur only when the business practices of an organization change, and only then, 
perhaps, a change in the culture will follow.  
These leaders also said that the patient safety movement will not be successful unless providers 
are held accountable for knowing the latest standards of care and for monitoring the outcomes of 
the care they provide. The development of a mandatory provider educational intervention for 
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VTE prophylaxis represents a change in business practices for both UWMC and HMC. Whether 
this change has an effect on patient safety will be measured in the post-implementation data 
collection period.  
Greenhalgh and colleagues’ recent systematic review of the diffusion of innovation literature 
emphasized that adoption is a process, not a one-time event, and that it is an interaction among 
the innovation, the intended adopter(s), and the context.
26 Furthermore, they emphasized that 
adoption is “an organic and often rather messy model of assimilation in which the organization 
moves back and forth between initiation, development, and implementation, variously 
punctuated by shocks, setbacks, and surprises.”  
The VTE interventions were officially implemented on March 12, 2008, during a ceremony on 
VTE prevention. Guest speakers from the VTE Safety Toolkit team, along with national 
spokesperson Melanie Bloom (coalition to Prevent DVT) also presented at the ceremony. 
Proclamations to support March as VTE prevention month in the State of Washington were 
signed by the Governor and the King County Council chair. Post-implementation data collection 
will begin in September 2008. The conceptual model put forth by Greenhalgh and colleagues
26 
guides the implementation content and processes for this study.  
Network Structures  
Various influences are involved in the spread of innovation, such as social network 
structures,
28, 29, 30 similarities in backgrounds between potential and current users of the 
innovation,
28, 30, 31 opinion leaders,
31, 32 organizational champions (e.g., physician champions, 
nurse champions),
33 boundary spanners (i.e., individuals with ties both inside and outside the 
organization in relation to the innovation),
34 and formal dissemination programs within 
organizations.
34 The structure and quality of social networks greatly influence the adoption of 
innovation by individuals, and these social networks vary by different groups of individuals and 
by the types of influence used within the groups.
26 These groups may be formal or informal, and 
the social networks can be described as horizontal or vertical. Physicians typically operate in 
formal, horizontal networks, which are considered more effective for supporting the construction 
and meaning and for spreading peer influence (peer to peer).
34 On the other hand, nurses operate 
more commonly in informal, vertical networks, which are considered more effective for passing 
on authoritative decisions and for organizing codified information.
30, 34  
The UWMC and HMC are academic medical centers with hierarchies within services. The 
network structures might be described as a combination of informal and formal and horizontal 
and vertical structures. Multiple providers—including nurses, physicians, and pharmacists—will 
be involved in the care of VTE patients, and understanding the network structures and cultures 
within these groups will aid in the successful dissemination and diffusion of the innovation. 
Physician, pharmacy, and nurse champions, expert opinion leaders, boundary spanners, and a 
formal dissemination program supported by UWMC and HMC will provide the context in which 
the innovation will be disseminated and diffused. After successful dissemination and evaluation 
of the post-implementation data, the interventions (VTE Safety Toolkit and On-line Provider 
Training Module on VTE Prophylaxis) will be made available nationally.  
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The VTE Safety Toolkit and On-line Provider Training Module for VTE Prophylaxis were not 
customized to be institution-specific, so that they would be applicable elsewhere after their 
effectiveness is tested at UWMC and HMC. Also, the processes and models for implementing 
the interventions and the dissemination strategies for translating the tools into practice will be 
shared.  
 
Conclusion 
VTE continues to be a national patient safety issue, and we have developed two educational 
interventions and recommendations for system changes that support the prevention and 
management of this clinical problem. The support of the administrations at both medical centers 
and the changes in the way training will be carried out for high-risk patient safety issues (VTE 
prophylaxis) is a change in business practices that hopefully will change the culture of safety. 
The organizational changes that support the VTE Safety Toolkit and On-line Provider Training 
Module on VTE Prophylaxis will improve patient safety and accountability around VTE. 
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